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Abstract
Background: Associations between selenium and cancer have directed attention to role of selenoproteins in the
carcinogenic process.
Methods: We used data from two population-based case-control studies of colon (n=1555 cases, 1956 controls) and rectal
(n=754 cases, 959 controls) cancer. We evaluated the association between genetic variation in TXNRD1, TXNRD2, TXNRD3,
C11orf31 (SelH), SelW, SelN1, SelS, SepX, and SeP15 with colorectal cancer risk.
Results: After adjustment for multiple comparisons, several associations were observed. Two SNPs in TXNRD3 were
associated with rectal cancer (rs11718498 dominant OR 1.42 95% CI 1.16,1.74 pACT 0.0036 and rs9637365 recessive 0.70
95% CI 0.55,0.90 pACT 0.0208). Four SNPs in SepN1 were associated with rectal cancer (rs11247735 recessive OR 1.30 95% CI
1.04,1.63 pACT 0.0410; rs2072749 GGvsAA OR 0.53 95% CI 0.36,0.80 pACT 0.0159; rs4659382 recessive OR 0.58 95% CI
0.39,0.86 pACT 0.0247; rs718391 dominant OR 0.76 95% CI 0.62,0.94 pACT 0.0300). Interaction between these genes and
exposures that could influence these genes showed numerous significant associations after adjustment for multiple
comparisons. Two SNPs in TXNRD1 and four SNPs in TXNRD2 interacted with aspirin/NSAID to influence colon cancer; one
SNP in TXNRD1, two SNPs in TXNRD2, and one SNP in TXNRD3 interacted with aspirin/NSAIDs to influence rectal cancer. Five
SNPs in TXNRD2 and one in SelS, SeP15, and SelW1 interacted with estrogen to modify colon cancer risk; one SNP in SelW1
interacted with estrogen to alter rectal cancer risk. Several SNPs in this candidate pathway influenced survival after
diagnosis with colon cancer (SeP15 and SepX1 increased HRR) and rectal cancer (SepX1 increased HRR).
Conclusions: Findings support an association between selenoprotein genes and colon and rectal cancer development and
survival after diagnosis. Given the interactions observed, it is likely that the impact of cancer susceptibility from genotype is
modified by lifestyle.
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Introduction
Selenoproteins are a class of proteins with the amino acid
selenocysteine that contains the active form of selenium [1].
Studies reporting associations between selenium and cancer, and
particularly colon cancer [2,3], have directed attention to role of
selenoproteins in the carcinogenic process. Twenty-five human
selenoprotein genes have been identified [4], with most research
focusing on the glutathione peroxidases (GPXs) and selenoprotein
P (SePP1) which is involved in selenium transport [5]. However,
given the biological properties of selenoproteins and their roles in
control of intracellular redox environment, cellular growth, and
defense against oxidative stress, it is feasible that other selenopro-
teins, such as thioredoxin reductase (TXNRD), selenoprotein W
(SelW), selenoprotein N (SelN), selenoprotein S (SelS), selenopro-
tein H (SelH), selenoprotein X (SepX), and 15-kDa selenoprotein
(SeP15) also may be involved in the carcinogenic process [4,6].
Thioredoxin reductases catalyze the NADPH-dependent re-
duction of oxidized thioredoxin [7]. Thioredoxins are catalyzing
agents that prevent cumulative oxidative stress, a factor that has
been linked to cell death and carcinogenesis and is an important
factor for controlling cellular redox regulation [8]. Humans have
three thioredoxin reductases which reduce different substrates in
different cellular compartments [9,10,11]: thioredoxin reductase 1
(TXNRD1), thioredoxin reductase 2 (TXNRD2), and thioredoxin
reductase 3 (TXNRD3). SeP15 is structurally similar to the
thioredoxin family. It is located primarily in the endoplasmic
reticulum and is involved in the induction of apoptosis and exhibits
redox activity [1,12]. SepW has been shown to be expressed in the
intestinal tract and studies have shown that it also exhibits
oxidation-reduction activity and possible antioxidant properties
[13,14]. SelS attenuates inflammation by decreasing pro-inflam-
matory cytokines [15]. SelN, SelH and SelX, although thought to
have biological functions that involve redox functions and
antioxidant properties, have been less well studied [4,14].
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polymorphism in TXNRD1, TXNRD2, TXNRD3, C11orf31 (i.e.
SelH), SelW, SelN1, SelS, SepX, and SeP15 and colon and rectal
cancer. Results on GPX and SelP from study data have been
previously assessed [16]. Given the hypothesized association
between these genes and oxidative stress, we evaluate diet and
lifestyle exposures that may influence observed colorectal cancer
risk associated with these genes. Dietary antioxidants have been
associated with other genes that mediate oxidative stress [17] and
could likewise interact with these genes. Cigarette smoking can
increase levels of oxidative stress; use of aspirin and non-steroidal
anti-inflammatory drugs can reduce inflammation and thus reduce
oxidative stress; BMI has been associated with increased inflam-
mation which can lead to oxidative stress. We evaluate estrogen
status since studies have shown an association between estrogen
status and selenium [18,19]; HRT use has been shown to reduce
risk of colorectal cancer. We also evaluate if genetic variation in
these selenoprotein genes influences survival after diagnosis with
colon or rectal cancer since previous studies shown that SeP15 is
associated with metastasis of colon cancer cells [20]. This expands
on the work of others that have proposed that a combination of
low selenium and SNPs in selonoprotein genes can enhance the
risk of colorectal cancer [14]
Methods
Two study populations are included. The first, a population-
based case-control study of colon cancer, included cases
(n=1,555) and controls (n=1,956) identified between October
1, 1991 and September 30, 1994 living in the Twin Cities
Metropolitan Area, Kaiser Permanente Medical Care Program of
Northern California (KPMCP) and a seven-county area of Utah
[21]. The second study used identical data collection methods as
the first study but included population-based cases with cancer of
the rectosigmoid junction or rectum (n=754) and controls
(n=959) who were identified between May 1997 and May 2001
in Utah and KPMCP [22]. Eligible cases were between 30 and 79
years old at time of diagnosis, English speaking, mentally
competent to complete the interview, no previous history of
CRC, and no known (as indicated on the pathology report)
familial adenomatous polyposis, ulcerative colitis, or Crohn’s
disease. Controls were matched to cases by sex and by 5-year age
groups. At KPMCP, controls were randomly selected from
membership lists. In Utah, controls 65 years and older were
randomly selected from the Health Care Financing Administra-
tion lists and controls younger than 65 years were randomly
selected from driver’s license lists. In Minnesota, controls were
selected from driver’s license and state-identification lists. Study
details have been reported [21,22]. The Study was approved by
the Institutional Review Board at the University of Utah. All
participants signed informed consent.
Data were collected by trained and certified interviewers using
laptop computers. All interviews were audio-taped and reviewed
for quality control purposes [23]. The referent period for recall of
diet and physical activity was two years prior to diagnosis for cases
and prior to selection for controls. Detailed information was
collected on diet [24], physical activity, medical history, cigarette
smoking history, regular use of aspirin and non-steroidal anti-
inflammatory drugs, and body size. Dietary data were collected on
all participants using an extensive diet history questionnaire [25].
For those foods reported, we obtained information on quantity,
frequency, and method of preparation. Foods were converted to
nutrients using the Minnesota Nutrition Coding Center nutrient
database. The body mass index (BMI) of kg/m
2 was calculated
from height measured at the time of the interview and weight
recalled for the referent period of two years prior to diagnosis or
selection. In instances where weight two years prior to diagnosis
was unavailable, we used weight reported for five years prior to
diagnosis or interview. Recalled weight was used to avoid possible
misclassification of weight from weight loss attributed to cancer.
Tumor registry data were obtained to determine disease stage at
diagnosis, months of survival after diagnosis, cause of death and
contributing cause of death. Disease stage was categorized by
Surveillance, Epidemiology, and End Results (SEER) staging of
local, regional, and distant disease as well as by the American Joint
Committee on Cancer (AJCC) staging criteria.
TagSNPs were selected using the following parameters: LD
blocks were defined using a Caucasian LD map and an r
2=0.8;
minor allele frequency (MAF) .0.1; range=21500 bps from the
initiation codon to +1500 bps from the termination codon; and 1
SNP/LD bin. This procedure generated two markers for SelS,
three for SeP15, five for SelN1, three for SelW1, two for SepX1, one
for C11of31, eight for TXNRD1, twenty for TXNRD2, and five for
TXNRD3. All markers were genotyped using a multiplexed bead-
array assay format based on GoldenGate chemistry (Illumina, San
Diego, California). A genotyping call rate of 99.85% was attained.
Blinded internal replicates represented 4.4% of the sample set; the
duplicate concordance rate was 100%. Individuals with missing
genotype data were not included in the analysis for that specific
marker.
Statistical analyses were performed for each study independent-
ly using SASH version 9.2 (SAS Institute, Cary, NC). The minor
allele frequency (MAF) and test for Hardy-Weinberg Equilibrium
(HWE) were calculated among white controls using the SAS
ALLELE procedure. We report odds ratios (ORs) and 95%
confidence intervals (CIs) assessed from adjusted multiple logistic
regression models adjusting for age, center, race/ethnicity, and
sex, which were matching variables for the original studies.
Analysis for interaction was based on tagSNPs within each gene.
All other SNPs were evaluated first by comparing the heterozygote
and homozygote variant to the homozygote wildtype and
subsequently assessing the dominant and recessive models; the
best fitting model is presented.
Diet and lifestyle variables for assessment with candidate genes
were selected because of their biological plausibility for involve-
ment in this candidate pathway. Interactions between genes and
hypothesized exposures associated with inflammation and oxida-
tive stress included daily consumption of vitamin C, vitamin E,
selenium, and beta carotene, recent aspirin or NSAID use,
cigarette smoking status, BMI, and estrogen status. Nutrients
reported were categorized based on sex-specific quartiles among
the controls, collapsing the second and third quartiles to form an
intermediate group. In addition to the minimal adjustments,
logistic regression models involving dietary variables also control
for total energy intake. P values for interaction were determined
using a 1df likelihood-ratio test comparing a full model that
included an interaction term with a reduced model without an
interaction term. For genetic and environmental factors that have
a 20% prevalence among controls with have 80% power to detect
an OR of 1.87 for colon cancer and 2.30 for rectal cancer; for
those with a 30% prevalence we have power to detect a 1.77 for
colon and 2.15 for rectal when using a 5% significance levels The
p values based on 1 degree of freedom (1-df) Wald test statistics for
the main effect models were adjusted for multiple comparisons
taking into account tagSNPs within the gene, using the methods of
Conneely and Boehnke [26] via R version 2.12.0 (R Foundation
for Statistical Computing, Vienna, Austria). The interaction p
values, based on 1-df likelihood-ratio tests, were adjusted using the
Selenoproteins and Colorectal Cancer
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Chromosome Location Major/Minor Allele FDR HWE
Symbol Alias SNP MAF
1
C11orf31 C17orf10, SELH 11q12.1 rs9420 G/A 0.32 0.95
SelS AD-015, ADO15 15q26.3 rs9874 A/G 0.14 1.00
MGC104346, MGC2553 rs4965814 T/C 0.18 1.00
SBBI8, SEPS1, VIMP
SeP15 1p31 rs2783974 G/A 0.12 0.75
rs486133 T/C 0.20 1.00
rs9433110 G/A 0.07 0.95
SelN1 FLJ24021 1p36.13 rs718391 C/G 0.47 1.00
MDRS1 rs2072749 A/G 0.27 1.00
RSMD1 rs11247735 G/A 0.47 1.00
RSS rs4659382 C/G 0.28 0.96
SEPN rs2294228 T/G 0.21 1.00
SelW1 SepW 19q13.3 rs10412896 T/C 0.35 0.98
rs3786777 G/T 0.49 1.00
rs2042286 C/T 0.39 0.98
SepX1 HSPC270, MGC3344 16p13.3 rs13331553 T/C 0.29 1.00
MSRB1, SELR, SELX rs732510 A/G 0.43 1.00
TXNRD1 GRIM-12 12q23-q24.1 rs4964778 C/G 0.18 0.97
MGC9145 rs4964779 T/C 0.11 1.00
TR rs4523760 T/C 0.23 0.74
TR1 rs5018287 G/A 0.45 1.00
TRXR1 rs4964287 C/T 0.32 0.91
TXNR rs17202060 C/T 0.34 0.58
rs7962759 C/G 0.22 1.00
rs11610799 G/C 0.08 1.00
TXNRD2 SELZ 22q11.21 rs1044732 A/G 0.15 0.95
TR rs3788305 A/G 0.47 1.00
TR-BETA rs3788306 T/C 0.30 1.00
TR3 rs2073750 G/A 0.23 1.00
TRXR2 rs9606173 A/T 0.15 0.96
rs5992493 A/G 0.17 1.00
rs3788314 G/A 0.46 1.00
rs3788317 G/T 0.23 0.98
rs7410379 G/A 0.29 1.00
rs756661 T/C 0.45 0.97
rs5748469 C/A 0.35 0.98
rs17745445 G/A 0.15 1.00
rs1978058 C/T 0.38 0.81
rs8141691 G/A 0.37 0.68
rs9306229 C/T 0.24 0.48
rs4333017 C/T 0.14 0.98
rs5746847 C/T 0.44 1.00
rs9605030 C/T 0.14 1.00
rs6518591 A/G 0.19 0.58
rs2020917 C/T 0.27 0.97
TXNRD3 TGR 3q21.3 rs4679274 C/T 0.34 1.00
TR2 rs777226 G/A 0.22 0.95
TRXR3 rs777238 C/T 0.13 0.68
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values from the main effect models and interaction p values based
on likelihood-ratio tests were used to calculate multiple compar-
isons. We consider a p value of 0.10 to be potentially important for
adjusted main effects and survival analysis given the candidate
pathway approach we have used in this study. Since we are using
the highly conservative Bonferroni method for adjustment of
multiple comparisons for interactions, we consider a p value of
0.15 or less as potentially important so that we are able to consider
both type 1 and type 2 errors. Additionally, we used a maxT
permutations procedure [28] to further evaluate interactions and
correspondingly adjust for multiple comparisons. Using the highly
efficient methods of Welbourn [29], 100,000 max T permutations
were performed for GXE pairing. Hypothesis tests involving
genotype and lifestyle exposure combinations between an individ-
ual SNP and a single lifestyle variable were mutually adjusted by
comparing each observed test statistic to the permutation null
distribution of the maximum test statistic over all tests conducted
upon that SNP. This adjustment was then expanded to mutually
adjust for all pairings between a single lifestyle variable and all
SNPs within a gene. This method also allowed for partitioning of
the data to better identify and categorize the most meaningful
groups where the interactions occurred. The maxT statistic
complements other methods of multiple comparison adjustment
by further defining the interaction as well as by using a more
robust permutations adjustment for multiple comparisons. For
survival analysis, multiple comparison adjustments were done
using the false discovery rate (FDR) adjusted p values using the
SAS MULTTEST procedure.
Survival-months were calculated based on month and year of
diagnosis and month and year of death or date of last contact.
Associations between SNPs and risk of death due to colorectal
cancer were evaluated using Cox proportional hazards models to
obtain adjusted hazard rate ratios (HRRs) and corresponding 95%
confidence intervals. We adjusted for age at diagnosis, study
center, race, sex, tumor molecular phenotype, and AJCC stage to
estimate HRRs and censored individuals at date of last contact or
death. Tumor molecular phenotype was determined from DNA
obtained from paraffin-embedded tissue. We have previously
sequenced hot spots for TP53 and KRAS, and assessed CpG Island
Methylator Phenotype (CIMP), and microsatellite instability (MSI)
[30,31,32,33].
Results
The tagSNPs analyzed are shown in Table 1; all SNPs are in
HWE. SNPs that were independently associated with colon and
rectal cancer are shown in Table 2. Although three SNPs in
TXNRD1, TXNRD2 and SelN1 were associated with colon cancer,
none remained statistically significant after adjustment for multiple
comparisons as indicated by the pACT. TXNRD2 (3 SNPs),
TXNRD3 (3 SNPs), SelN1 (3 SNPs), and SepX1 (1 SNP) were
associated with rectal cancer. While SNPs in TXNRD2 and SepX1
did not remain statistically significant after adjustment for multiple
comparisons, those in TXNRD3 and SelN1 were statistically
significant after multiple comparison adjustments with pACT.
We observed statistically significant interaction with aspirin/
NSAIDs and smoking with several candidate genes (Table 3). The
most common interaction with aspirin followed the pattern of
lower risk for the variant allele among NSAID users. Interactions
between aspirin/NSAIDs with TXNRD1 rs4964778 remained
statistically significant for colon cancer after adjustment for
multiple comparison; rs17745445 of TNXRD2 was borderline
significant after adjustment for multiple comparison with the step-
down Bonferroni correction. Two SNPs in TXNRD2 interacted
significant with cigarette smoking for colon cancer where those
who smoked were at greater risk with the variant allele;
associations were not statistically significant after adjustment for
multiple comparisons. For rectal cancer four SNPs in TXNRD1,
TXNRD2, and TXNRD3 interacted with aspirin/NSAID use and
two SNPs in TXNRD1 interacted with cigarette smoking; the step-
down Bonferroni correction was greater than 0.15 for all of these
associationsFor rectal cancer and aspirin, the greatest effect of the
genes appeared to be among non-NSAID users while among those
who smoked cigarettes the variant allele appeared to reduce the
risk of rectal cancer associated with smoking. The maxT, which is
more robust for adjustment of multiple comparisons than the step-
down Bonferroni correction, showed statistically significant
interaction with all SNPS identified as interacting with aspirin/
NSAID use for both colon and rectal cancer.
Only TXNRD3 rs11718498 and rs777226 were associated with
vitamin E and beta carotene respectively after adjustment for
multiple comparisons (Table S1) shows dietary variables associated
with SNPs prior to adjustment and the corresponding p value after
multiple comparison adjustment). In both instances those with low
intake had reduced colon cancer risk in the presence of the variant
genotype, while those with high intake were at reduced intake in
the presence of wildtype and heterozygote variant.
We observed numerous statistically significant interactions
between candidate genes, TXNRD2, SelS, SeP15, and SelW1 and
estrogen status for both colon and rectal cancer (Table 4). While
the variant alleles often increased risk among those not exposed to
estrogen, they appeared to reduce risk among those exposed to
estrogen. Roughly 50% of the SNPs initially associated showed a
significant interaction after adjustment for multiple comparisons.
Utilization of the maxT highlighted the focus of the interactive
effects with most interactions remained statistically significant with
this approach. In general, the estrogen status had a more
pronounced effect depending on genotype of these candidate
selenoprotein genes.
TXNRD1, TXNRD2, TXNRD3, and SelN1 interacted with BMI
to alter risk of colon cancer and TXNRD1 interacted with BMI to
statistically alter risk associated with rectal cancer (Table 5). The
adjusted risk for SelN1 and colon cancer and both TXNRD1 SNPs
and rectal cancer remained statistically significant after adjustment
Table 1. Cont.
Chromosome Location Major/Minor Allele FDR HWE
Symbol Alias SNP MAF
1
rs9637365 C/T 0.42 0.85
rs11718498 G/A 0.42 0.05
1Minor Allele Frequency (MAF) and FDR-adjusted Hardy-Weinberg Equilibrium (FDR HWE) based on white control population.
doi:10.1371/journal.pone.0037312.t001
Selenoproteins and Colorectal Cancer
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the cancer risk associated with obesity was influenced by genotype.
We evaluated these candidate selenoprotein genes with hazard
of dying of colorectal cancer after diagnosis with colon or rectal
cancer (Table 6). TXNRD1, TXNRD3, SeP15, and SepX1 were
associated with survival after colon cancer diagnosis; SeP15 and
SepX1 remained significant after FDR multiple comparison
adjustment (HRR 1.47, 95% CI 1.13,1.90 and HRR 1.47 95%
Table 2. Associations between TXNRD1, TXDRD2, TXNRD3, SelN1, and SepX1 and colon and rectal cancer.
Colon Cancer Controls Cases OR
1 (95% CI) Raw PP ACT
TXNRD1 (rs17202060) 0.0209 0.1251
CC/CT 1722 1324 1.00
TT 232 222 1.26 (1.04 1.54)
TXNRD2 (rs3788317) 0.0266 0.3341
GG/GT 1859 1448 1.00
TT 96 107 1.38 (1.04 1.84)
SelN1 (rs4659382)
CC/CG 1797 1458 1.00 0.0383 0.1428
GG 156 95 0.76 (0.58, 0.98)
Rectal Cancer
TXNRD2 (rs1044732) 0.0361 0.4002
AA 685 575 1.00
AG/GG 270 176 0.79 (0.63 0.98)
TXNRD2 (rs5748469) 0.0139 0.2017
CC/CA 833 620 1.00
AA 125 134 1.40 (1.07 1.83)
TXNRD2 (rs5992493) 0.0277 0.3360
AA 619 521 1.00
AG/GG 340 233 0.79 (0.65 0.98)
TXNRD3 (rs11718498) 0.0008 0.0036
GG 361 227 1.00
GA/AA 598 527 1.42 (1.16 1.74)
TXNRD3 (rs4679274) 0.0339 0.0919
CC/CT 824 670 1.00
TT 135 83 0.73 (0.54 0.98)
TXNRD3 (rs9637365) 0.0059 0.0208
CC/CT 757 631 1.00
TT 202 123 0.70 (0.55 0.90)
SelN1 (rs11247735) 0.0213 0.0410
GG/GA 753 554 1.00
AA 206 200 1.30 (1.04, 1.63)
SelN1 (rs2072749) 0.0035 0.0159
AA 484 422 1.00
AG 394 294 0.86 (0.70, 1.05)
GG 81 38 0.53 (0.36, 0.80)
SelN1 (rs4659382) 0.0067 0.0247
CC/CG 876 716 1.00
GG 81 38 0.58 (0.39, 0.86)
SelN1 (rs718391) 0.0113 0.0300
CC 250 239 1.00
CG/GG 709 515 0.76 (0.62, 0.94)
SepX1 (rs732510) 0.0310 0.0565
AA/AG 763 563 1.00
GG 192 187 1.29 (1.02, 1.63)
1Associations adjusted for age, sex, race, and study center.
doi:10.1371/journal.pone.0037312.t002
Selenoproteins and Colorectal Cancer
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colon and rectal cancer.
Controls Cases OR






Colon Cancer No Recent Aspirin/NSAID Use Recent Aspirin/NSAID Use
TXNRD1 (rs4523760) 0.0234 0.1638 G={1,2} &
E=1
,0.0001
TT 686 612 1 459 304 0.75 (0.62, 0.90)
TC/CC 449 439 1.09 (0.92, 1.30) 345 180 0.59 (0.47, 0.72)
TXNRD1 (rs4964778) 0.0026 0.0208 G={1,2} &
E=1
,0.0001
CC 779 691 1.00 524 350 0.76 (0.64, 0.90)
CG/GG 356 361 1.14 (0.95, 1.37) 280 135 0.54 (0.43, 0.68)
TXNRD2 (rs17745445) 0.0039 0.0780 G={1,2} &
E=1
0.0020
GG 855 756 1.00 580 375 0.74 (0.63, 0.87)
GA/AA 281 297 1.20 (1.00, 1.46) 223 110 0.55 (0.43, 0.71)
TXNRD2 (rs3788314) 0.0198 0.3762 G={1,2} &
E=0
,0.0001
GG 350 271 1.00 237 145 0.80 (0.62, 1.05)
GA 561 527 1.22 (1.00, 1.48) 381 239 0.81 (0.65, 1.02)
AA 225 251 1.41 (1.11, 1.80) 181 101 0.70 (0.52, 0.94)
TXNRD2 (rs5992493) 0.0207 0.3762 G={1,2} &
E=0
0.0023
AA 794 691 1.00 553 349 0.73 (0.62, 0.87)
AG/GG 342 362 1.20 (1.00, 1.43) 250 136 0.61 (0.48, 0.77)
TXNRD2 (rs756661) 0.0401 0.6817 G in {0 1) &
E=0
,0.0001
TT 353 364 1.00 257 141 0.53 (0.41, 0.68)
TC 548 503 0.90 (0.75, 1.10) 373 239 0.63 (0.51, 0.79)
CC 235 184 0.78 (0.61, 0.99) 172 105 0.62 (0.46, 0.82)
Non-Smoker/Non-Recent Smoker Recent Smoker
TXNRD2 (rs17745445) 0.0388 0.7372 G={1,2} &
E=1
0.4918
GG 1180 920 1.00 265 223 1.04 (0.85, 1.28)
GA/AA 428 314 0.94 (0.79, 1.11) 81 95 1.47 (1.08, 2.00)
TXNRD2 (rs5992493) 0.0241 0.4820 G={1,2} &
E=1
0.1540
AA 1102 846 1.00 254 206 1.02 (0.83, 1.26)
AG/GG 506 388 0.97 (0.83, 1.14) 92 112 1.52 (1.13, 2.03)
Rectal Cancer No Recent Aspirin/NSAID Use Recent Aspirin NSAID Use
TXNRD1 (rs4964778) 0.0380 0.3040 G={1,2} &
E=1
0.0404
CC 364 321 1.00 283 198 0.80 (0.63, 1.02)
CG/GG 157 156 1.15 (0.88, 1.50) 144 73 0.59 (0.43, 0.81)
TXNRD2 (rs1978058) 0.0446 0.8474 G={0,1} &
E=1
0.0141
CC 203 214 1.00 190 110 0.56 (0.41, 0.75)
CT 248 202 0.78 (0.60, 1.02) 186 119 0.62 (0.46, 0.84)
TT 70 61 0.84 (0.57, 1.25) 51 42 0.80 (0.51, 1.26)
TXNRD2 (rs9606173) 0.0353 0.7060 G=0 & E=1 0.0145
AA 344 334 1.00 316 185 0.61 (0.48, 0.77)
AT/TT 177 143 0.83 (0.63, 1.08) 111 86 0.80 (0.58, 1.10)
Selenoproteins and Colorectal Cancer
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associated with survival after diagnosis with rectal cancer. SelN1
rs718391 (HRR 1.67, 95% CI 1.11,2.51) and SepX1 rs13331553
(HRR 1.46 95%CI 1.07,2.00) and SepX1 rs732510 (HRR 1.68
95% CI 1.09,2.60) had FDR of ,0.10.
Discussion
We observed associations between selenoprotein genes and
colon and rectal cancer risk overall as well as from interacting with
variables that may influence oxidative stress, including NSAIDs,
cigarette smoking, BMI, and estrogen status. However, we
observed only minimal interaction with dietary antioxidants,
including selenium. In these data TXNRD1, TXNRD2, TNXRD3,
SepX1, and SelN1, and SeP15 also were associated with survival
after diagnosis with colon or rectal cancer. C11orf31 was not
associated with colon and rectal cancer through either main or
interactive effects.
The thioredoxin system is a major antioxidant system central to
intracellular oxidation processes [34,35,36]. The major indepen-
dent associations were observed for TXNRD1, TXNRD2,
TXNRD3, and SelN. While associations with most SNPs were
different for colon and rectal cancer, the same genes appeared to
be important. However, SelN rs4659382 was associated with
significant reduced risk of both colon cancer (OR 0.76) and rectal
cancer (OR 0.58). Additionally, multiple SNPs in SelN were
associated with rectal cancer, as were multiple SNPs in TXNRD2
for both colon and rectal cancer, although associations did not
reach significance after adjustment for multiple comparisons.
Others have shown significant associations between TXNRD1
rs35009941 and colorectal adenomas [37]. Given the extremely
rare minor allele frequency of that SNP (only one case of 747 were
homozygote variant and four were heterozyote for the variant
allele in their study), we did not genotype that SNP. A study by
Meplan and colleagues also evaluated several of these genes
combining colon and rectal cancers [38]. They observed a
significant association with SelS, attributing to an inflammation-
related pathway; SelS has been shown to attenuate inflammation
by decreasing pro-inflammatory cytokines [15]. We did not
observe an independent association with SelS. Hesketh and
Meplan have hypothesized that genetic factors could modulate
effects at multiple points along a network of pathways [39].
Pathways they cite as potentially important links between
selenium, selenoproteins, and colon cancer involve oxidative
stress, inflammation, and apoptosis.
Given the hypothesized influence of selenoproteins on oxidative
stress and inflammation-related pathways, it is reasonable to
determine if factors that alter inflammation such as aspirin/
NSAID use and cigarette smoking could modify the risk associated
with the genes. We observed that TNXRD1 and TNXRD2
interacted with both aspirin and cigarette smoking to alter colon
and rectal cancer risk. TNXRD3 also interacted with aspirin/
NSAID use to modify risk of rectal cancer, in that those with the
variant genotype who did not use aspirin/NSAID had a similar
reduced risk of rectal cancer as those who used aspirin/NSAIDs.
These findings suggest that the risk associated with either not using
aspirin/NSAID or smoking cigarettes may be influenced by
genotype of several selenoprotein genes.
Of interest was the observed interaction between a number of
SNPs in selenoprotein genes and estrogen status. Estrogen has
anti-inflammatory properties, which could explain some of these
associations. However, it also has been shown that estrogen
influences tissue distribution and metabolism of selenium [19]. In
vitro interaction studies have shown interaction between a splicing
variant of TXNRD1b and both ERa and ERb and concluded that
it was an important modulator of estrogen signaling [18]. Other
selenoproteins could have similar associations with estrogen status.
In this study, we observed significant interactions with TXNRD2,
SelS, SeP15, and SelW with estrogen status, although significance
was reduced after multiple comparison adjustment. Although the
same SNPs were not associated with colon and rectal cancer, both
TXNRD2 and SELW were associated with both tumor sites.
Recent estrogen exposure has been associated with reduced risk of
colon and rectal cancer; selenoprotein genotypes appear to
influence that association.
Of interest was the observation that BMI reacted in a similar
manner with TXNRD1, TXNRD2, and TXNRD3 as did aspirin/
NSAIDs, and smoking cigarettes, and estrogen status. The
mechanism underlying these interactions could involve both an
inflammation-related pathway and an estrogen-related pathway.
The colon and rectal cancer risk associated with BMI was
influenced by genotype of these genes. The interaction with BMI
Table 3. Cont.
Controls Cases OR






TXNRD3 (rs9637365) 0.0265 0.1325 G={0,1} &
E=0
0.0002
CC 164 179 1.00 147 83 0.52 (0.37, 0.74)
CT 241 226 0.86 (0.65, 1.14) 197 138 0.65 (0.48, 0.88)
TT 116 72 0.55 (0.38, 0.79) 84 50 0.53 (0.35, 0.81)
Non-Smoker/Non-Recent SmokerRecent Smoker
TXNRD1 (rs17202060)
CC 369 237 1.00 64 76 1.82 (1.25, 2.64) 0.0274 0.2192 G=0 & E=0 0.1078
CT 329 290 1.38 (1.10, 1.73) 65 58 1.35 (0.91, 2.00)
TT 110 75 1.06 (0.76, 1.48) 21 14 0.97 (0.48, 1.96)
1Odds Ratios (OR) and 95% Confidence Intervals (CI) adjusted for age, study center, race, and sex.
2G=numerical coding (i.e., 0, 1, 2) for the SNP; E=numerical coding (i.e., 0, 1) for the environmental factor.
doi:10.1371/journal.pone.0037312.t003
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associations with BMI overall appear to influence colon but not
rectal cancer [21,40]. We are unaware of others evaluating the
interaction between lifestyle factors and genetic variation in
selenoprotein genes. Our results suggest that genetic risk is
modified by lifestyle, but confirmation of these findings by others
is needed.
Studies have shown that the thioredoxin system can predict
prognosis of other types of cancer [34]. SeP15 has been shown to
inhibit tumorigenicity and metastasis of colon cancer cells [20]. In
the study by Irons, they observed that SeP15 influenced expression
patterns of over 1000 genes in mice. Those genes that were most
commonly influenced were those whose biological function
included cellular growth and proliferation. We observed differ-
ences in likelihood of dying for several selenoprotein genes,
Table 4. Associations between TXNRD and selenoprotein SNPs and estrogen and risk of colon and rectal cancer.
Controls Cases OR






Colon Cancer No Recent Estrogen Exposure Recent Estrogen Exposure
TXNRD2 (rs17745445) 0.0011 0.0220 G={1,2} &
E=1
0.0077
GG 410 336 1.00 251 180 0.72 (0.54, 0.95)
GA/AA 113 113 1.24 (0.92, 1.68) 109 42 0.39 (0.26, 0.59)
TXNRD2 (rs3788314) 0.0015 0.0270 G={1,2} &
E=1
0.0121
GG 177 121 1.00 88 73 1.01 (0.67, 1.52)
GA 244 219 1.32 (0.98, 1.77) 186 102 0.65 (0.46, 0.94)
AA 98 107 1.57 (1.09, 2.25) 86 46 0.62 (0.40, 0.98)
TXNRD2 (rs3788317) 0.0012 0.0228 G={1,2} &
E=1
0.0083
GG 332 261 1.00 193 145 0.78 (0.58, 1.06)
GT/TT 191 188 1.24 (0.96, 1.61) 167 77 0.47 (0.34, 0.67)
TXNRD2 (rs5992493) 0.0197 0.2955 G={1,2} &
E=1
0.1093
AA 374 305 1.00 241 167 0.69 (0.52, 0.92)
AG/GG 149 144 1.15 (0.87, 1.53) 119 55 0.46 (0.31, 0.67)
TXNRD2 (rs756661)
TT 152 159 1.00 132 63 0.38 (0.25, 0.56) 0.0101 0.1717 G=0 & E=1 0.1076
TC 252 201 0.79 (0.59, 1.06) 163 112 0.55 (0.38, 0.79)
CC 118 89 0.75 (0.52, 1.07) 65 46 0.58 (0.36, 0.92)
SelS (rs9874) 0.0359 0.0718 G={1,2} &
E=0
0.0109
AA 392 306 1.00 251 160 0.67 (0.50, 0.89)
AG/GG 131 143 1.39 (1.05, 1.84) 110 62 0.56 (0.39, 0.82)
SeP15 (rs2783974) 0.0236 0.0708 G=0 & E=0 0.0018
GG 412 379 1.00 292 171 0.52 (0.40, 0.68)
GA/AA 111 70 0.69 (0.50, 0.96) 69 51 0.66 (0.43, 1.01)
SepW1 (rs3786777) 0.0037 0.0111 G=2 & E=1 0.0168
GG/GT 399 320 1.00 259 178 0.7 (0.53, 0.93)
TT 123 129 1.27 (0.95, 1.70) 102 44 0.43 (0.29, 0.64)
Rectal Cancer
TXNRD2 (rs2073750) 0.0065 0.1300 G=0 & E=0 0.5276
GG 84 86 1.00 151 84 0.45 (0.29, 0.69)
GA/AA 85 55 0.62 (0.39, 0.97) 98 77 0.64 (0.41, 1.01)
SepW1 (rs2042286) 0.0016 0.0048 G=2 & E=1 0.0423
CC/CT 151 119 1.00 211 150 0.77 (0.54, 1.09)
TT 17 22 1.71 (0.87, 3.38) 38 10 0.28 (0.13, 0.59)
1Odds Ratios (OR) and 95% Confidence Intervals (CI) adjusted for age, study center, race, and sex.
2G=numerical coding (i.e., 0, 1, 2) for the SNP; E=numerical coding (i.e., 0, 1) for the environmental factor.
doi:10.1371/journal.pone.0037312.t004
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variation in selenoprotein genes may influence survival after
diagnosis.
Major strengths of our study were the hypothesis-driven
approach, the large and extensive data set that includes
information on genetic, diet, and lifestyle data, and our ability to
examine colon and rectal cancer separately. While we believe that
the data we present are both thorough and informative, we
acknowledge that limitations exist. For instance, while we have
detected associations we have minimal information on the
functionality of the SNPs evaluated. Additional lab-based exper-
iments are needed to determine functionality. Through our
analysis we have made many comparisons. We used several
methods to adjust for multiple comparisons, the pACT which
takes into account the correlated nature of the SNP data, the step-
down Holm Bonferroni to adjust for interaction associations, and
the maxT which relies on permutation methods. Several
interactions were significant after adjusting for multiple compar-
isons by both methods. The maxT method partitions the data into
categories that helps to describe the interaction while the step-
down Bonferroni statistic is based on our results from logistic
regression models that rely on a common referent point and test
for difference in effects across cells of environmental and genetic
exposures. We believe that these two methods are complimentary,
reinforcing the associations that are significant after multiple
testing adjustment and helping to define the elements of the data
that are interacting. However, we acknowledge the possibility of
chance findings and therefore replication of these results is critical.
Several potential weakness exist. Our study relied on recalled
dietary intake to evaluate nutrients such as selenium. Nutrient
databases for selenium content of foods can be inaccurate given
the selenium content of the soil influences selenium levels in food.
Information on source of food could not be obtained in a study
such as this given the lack of knowledge of where foods are grown
or the selenium content of soil, leaving the possibility of lack of
association from misclassification of selenium intake. Unfortunate-
ly, given the study design we do not have selenium measurements
that would more accurately reflect selenium levels of study
participants. Additionally, we have relied on self-reported weight
to calculate BMI. We were unable to evaluate change in weight
that may be associated. In our study, Hispanic and African
American participants had larger mean levels of BMI; however the
associations with colon cancer were the same across all ethnic
groups.
The study findings support an association between selenopro-
tein genes and colon and rectal cancer development and survival
after diagnosis. Given the interactions observed, it is likely that the
impact of cancer susceptibility from genotype is modified by
lifestyle factors. The data presented here support the role of
selenoproteins in the carcinogenic process and suggest that they
may function through pathways that involve inflammation,
oxidative stress, and estrogen.
Supporting Information
Table S1 Associations between dietary variables and selenopro-
tein genes, adjusted for age, center, race, sex, and kcal.
(DOCX)
Acknowledgments
The contents of this manuscript are solely the responsibility of the authors
and do not necessarily represent the official view of the National Cancer
Institute. We would like to acknowledge the contributions of Dr. Bette
Caan and the Kaiser Permanente Medical Research Program, Sandra
Edwards, Roger Edwards, Leslie Palmer, Donna Schaffer, Dr. Kristin
Anderson, Dr. John Potter, and Judy Morse for data management and
collection.
Author Contributions
Conceived and designed the experiments: MS RKW. Performed the
experiments: MS RKW. Analyzed the data: AL BW CC. Contributed
reagents/materials/analysis tools: BW CC. Wrote the paper: MS.
Table 6. Association between TNXRD and Selenoprotein










CG/GG 106/2561 1.28 (1.01, 1.63)
TXNRD3 (rs11718498) 0.0301 0.1503
GG/GA 265/6812 1.00
AA 44/1329 0.70 (0.50, 0.97)
SeP15 (rs9433110) 0.0154 0.0461
GG 254/6961 1.00
GA/AA 55/1187 1.45 (1.07, 1.95)
SepX1 (rs732510) 0.0038 0.0076
AA/AG 227/6370 1.00






GA/AA 115/3190 0.69 (0.49, 0.96)
TXNRD2 (rs756661) 0.0504 0.5042
TT/TC 139/3607 1.00
CC 32/682 1.50 (1.00, 2.24)
SelN1 (rs718391) 0.0144 0.0722
CC/CG 137/3482 1.00
GG 34/807 1.67 (1.11, 2.51)
SepX1 (rs13331553) 0.0178 0.0184
TT 78/2155 1.00
TC/CC 93/2135 1.46 (1.07, 2.00)
SepX1 (rs732510) 0.0184 0.0184
AA 41/1275 1.00
AG 80/1974 1.22 (0.83, 1.80)
GG 49/1022 1.68 (1.09, 2.60)
P Trend 0.0182
1Hazard Rate Ratios (HRR) adjusted for age, study center, race, sex, AJCC stage,
and tumor markers.
doi:10.1371/journal.pone.0037312.t006
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